Projects per year
Personal profile
Chinese Name
于媛媛
Research Interests
1) Optimization of aptamer selection methodology;
2) Aptamer-based translational medicine and drug discovery;
3) Aptamer structural biology
Biography
Prof. Yuanyuan Yu is a tenure track Assistant Professor in the School of Chinese Medicine. She earned her PhD in Biochemistry from Faculty of Medicine at the University of Hong Kong in 2015. Prof. Yu has undertaken multiple external grants in the capacity of PI (such as GRF-RGC and NSFC). Prof. Yu has focused on developing therapeutic aptamers for various diseases. Her research mainly focuses on aptamer-based drug discovery, including understanding disease mechanisms, identifying targets and discovering drug for diseases, particularly rare and geriatric diseases that lack specific treatments.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, The University of Hong Kong
1 Sept 2010 → 28 Feb 2015
Award Date: 21 Nov 2015
External positions
Guangdong‐Hong Kong Macao Greater Bay Area International Research Platform for Aptamer‐Based Translational Medicine and Drug Discovery
1 Jan 2017 → …
Keywords
- QH301 Biology
- Biochemistry
- Molecular Biology
- RM Therapeutics. Pharmacology
- Drug Discovery
- Aptamer
Fingerprint
Dive into the research topics where Yuanyuan YU is active. Topic labels come from the works of this scholar.
- 1 Similar Scholars
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Equipment Matching Fund - High-performance Slide Scanner
LIU, J. (PI), LI, F. (CoI), YU, Y. (CoI), XU, J. (CoI), FU, X. (CoI), WONG, H. L. X. (CoI), KWAN, H. Y. (CoI) & CHONG, W. P. (CoI)
26/03/24 → 25/03/26
Project: Research project
-
The role of the interactions between N domain and Linker 2 of DKK1 in modulating the immunosuppressive tumor microenvironment mediated by DKK1 C domain
YU, Y. (PI) & Li, P. (CoI)
1/01/23 → 30/06/25
Project: Research project
-
Targeting sclerostin loop3 to promote bone formation with low cardiovascular risk in animal models
YU, Y. (PI)
1/01/21 → 31/12/23
Project: Research project
-
Abstract A048: Intracellular DKK1 could play a vital role in promoting triple-negative breast cancer cell proliferation, migration, and invasion
Zhang, Y., Chen, Z., Pan, Y., Sun, M., Liu, Y., Chen, M., Luo, H., Kang, W., Lu, A., Yu, S., Yu, Y., Zhang, G. & Zhang, B., Mar 2025, In: Cancer Research. 85, 5, Supplement, A048.Research output: Contribution to journal › Conference article › peer-review
-
Classifications of triple-negative breast cancer: insights and current therapeutic approaches
Chen, Z., Liu, Y., Lyu, M., Chan, C. H., Sun, M., Yang, X., Qiao, S., Chen, Z., Yu, S., Ren, M., Lu, A., Zhang, G., Li, F. & Yu, Y., 1 Feb 2025, In: Cell and Bioscience. 15, 1, 16 p., 13.Research output: Contribution to journal › Journal article › peer-review
Open Access1 Citation (Scopus) -
DeepAptamer: Advancing high-affinity aptamer discovery with a hybrid deep learning model
Yang, X., Chan, C. H., Yao, S., Chu, H. Y., Lyu, M., Chen, Z., Xiao, H., Ma, Y., Yu, S., Li, F., Liu, J., Wang, L., Zhang, Z., Zhang, B. T., Zhang, L., Lu, A., Wang, Y., Zhang, G. & Yu, Y., 11 Mar 2025, In: Molecular Therapy Nucleic Acids. 36, 1, 15 p., 102436.Research output: Contribution to journal › Journal article › peer-review
Open Access -
Machine learning-powered, high-affinity modification strategies for aptamers
Amu, G., Yang, X., Luo, H., Yu, S., Zhang, H., Tian, Y., Yu, Y., Ding, S., Pan, Y., Chen, Z., He, Y., Ma, Y., Zhang, B. & Zhang, G., 30 Jan 2025, In: Acta Materia Medica. 4, 1, p. 122-136 15 p.Research output: Contribution to journal › Journal article › peer-review
Open Access -
Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters
Que, Z., Qi, D., Yang, Y., Yao, W., Liu, J., Li, Y., Yu, Y., Wang, L., Li, F., Zhang, G., Wu, E. & Tian, J., 24 Feb 2025, In: Cellular and Molecular Biology Letters. 30, 1, 18 p., 23.Research output: Contribution to journal › Journal article › peer-review
Open Access2 Citations (Scopus)
Prizes
-
2023 Geneva international inventions: silver prize
MA, Y. (Recipient) & YU, Y. (Recipient), 29 Apr 2023
Prize
-
An aptamer drug targeting sclerostin loop3 for bone anabolic therapy without increasing cardiovascular risk
YU, Y. (Recipient), Apr 2023
Prize: Award
-
First runner-up, Best Poster Award, The Blue Sky Research Fund Open Forum, HKBU
YU, Y. (Recipient), 2022
Prize: Award
-
President’s Award for Outstanding Performance in Early Career Researcher
YU, Y. (Recipient), 2024
Prize: Award
-
Activities
-
Molecular Therapy - Nucleic Acids (Journal)
YU, Y. (Reviewer)
Apr 2025Activity: Publication peer-review/editorial work › Editor/reviewer for publications (incl. CDCF T61 Journal Editor)
-
Molecular Pharmaceutics (Journal)
YU, Y. (Reviewer)
Apr 2025Activity: Publication peer-review/editorial work › Editor/reviewer for publications (incl. CDCF T61 Journal Editor)
-
Chemical Science (Journal)
YU, Y. (Reviewer)
Apr 2025Activity: Publication peer-review/editorial work › Editor/reviewer for publications (incl. CDCF T61 Journal Editor)
-
International Journal of Biological Macromolecules (Journal)
YU, Y. (Reviewer)
Mar 2025Activity: Publication peer-review/editorial work › Editor/reviewer for publications (incl. CDCF T61 Journal Editor)
-
International Journal of Biological Macromolecules (Journal)
YU, Y. (Reviewer)
Feb 2025Activity: Publication peer-review/editorial work › Editor/reviewer for publications (incl. CDCF T61 Journal Editor)
Press/Media
-
From Molecular Target to Aptamer Drug Discovery towards US-FDA Orphan Drug Designation
YU, Y., ZHANG, G., LYU, A. & WANG, L.
19/12/22 → 20/12/22
4 Media contributions
Press/Media